Stifel Maintains Buy on Aclaris Therapeutics, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Alex Thompson maintains a 'Buy' rating on Aclaris Therapeutics (NASDAQ:ACRS) and raises the price target from $16 to $20.
September 14, 2023 | 2:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel's raised price target for Aclaris Therapeutics suggests increased confidence in the company's performance.
The raised price target by Stifel indicates a positive outlook for Aclaris Therapeutics. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100